Nicole Willmarth Archives - American Brain Tumor Association

New Statistical Report Reveals Primary Brain and Central Nervous System Tumors as Second Most Common Cancer Type in Adolescents and Young Adults

CHICAGO (May 7, 2024)—Today, the American Brain Tumor Association (ABTA), in partnership with the National Institutes of Health’s National Cancer Institute (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) program and the Central Brain Tumor Registry of the United States (CBTRUS), unveiled a new report shedding light on the prevalence of primary brain and other central nervous system (CNS) tumors among adolescents and young adults (AYAs) between the ages of 15 and 39.

Minh Nguyen at the 2023 SNO Annual Meeting

Annual SNO Meeting Fosters Unprecedented Collaboration

Read our top takeaways from the Society for Neuro-Oncology (SNO) Annual Meeting, the world’s largest gathering of neuro-oncology experts.

ABTA Announces $1.3 Million in New Funding to Accelerate Adult and Pediatric Brain Tumor Research

The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages. Dedicated to advancing the field of neuro-oncology and accelerating the discovery of life-saving treatments, the ABTA is proud to have invested more than $35 million, to approximately 700 researchers to support 800 projects, to date.

ABTA Chief Mission Officer Nicole Willmarth, PhD, with neuro-oncology leaders at the White House Cancer Moonshot Brain Cancer Forum

Top Brain Tumor News & Milestones for 2023

From groundbreaking research to new collaborations at a federal level, discover the top three brain tumor news highlights and milestones for the year.

Your Long-Time Brain Tumor Champion Ups Its Game in Washington

With the reigniting of the White House’s Cancer Moonshot Initiative, the ABTA recently joined the Brain Cancers Forum in Washington, D.C., to discuss opportunities in discovering treatments for brain cancers, including GBM.

First Targeted Therapy for Glioma Headed for FDA Approval

A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”

American Brain Tumor Association Partners with Brain Tumour Foundation of Canada on Low-Grade Glioma Research

The American Brain Tumor Association (ABTA) today announced a new partnership with Brain Tumour Foundation of Canada (BTFC) to accelerate brain tumor research. Through this partnership, BTFC will invest in the ABTA research program to co-fund a research project in Canada, focused on improving resection for low-grade glioma.

American Brain Tumor Association Awards 20 Research Grants to Advance Brain Tumor Science and Discoveries

The American Brain Tumor Association (ABTA) today announced the funding of $821,000 towards 20 new research grants to advance brain tumor science and treatments. With more than $34 million invested in research to date, across all brain tumor types and ages, the ABTA research program plays a critical role in advancing the understanding of brain tumors and building the next generation of brain tumor researchers.